Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 3/2022

01-03-2022 | Disease Modifying Anti-Rheumatic Drug | Letter to the Editor

In response to comment on “Hip involvement in children with enthesitis-related arthritis (ERA) is associated with poor outcomes in adulthood” by Ferjani H L et al. 

Authors: R. Naveen, Namita Mohindra, Neeraj Jain, Sanjukta Majumder, Amita Aggarwal

Published in: Clinical Rheumatology | Issue 3/2022

Login to get access

Excerpt

We thank Ferjani HL et al. for their interest in our article “Hip involvement in children with enthesitis-related arthritis (ERA) is associated with poor outcomes in adulthood.” Hip involvement, axial involvement, and HLA-B27 positivity were the major predictors of poor long-term outcomes in adulthood [1]. We also observe in our clinic that early intra-articular hip injection with glucocorticoids within 3 months of symptom onset delays or prevents the hip disease from progressing. This is similar to data with IA injection of other peripheral joints [2, 3]. It would be a good practice to educate the patients for red flag signs of early hip involvement apart from uveitis which is usually told to the patient. …
Literature
1.
Naveen R, Mohindra N, Jain N, Majumder S, Aggarwal A (2021) Hip involvement in children with enthesitis related arthritis (ERA) is associated with poor outcomes in adulthood. Clin Rheumatol 40(11):4619–4627CrossRef
2.
Gotte A (2009) Intra-articular corticosteroids in the treatment of juvenile idiopathic arthritis: safety, efficacy, and features affecting outcome. A comprehensive review of the literature. Open Access Rheumatol Res Rev 37
3.
Nieto-González JC, Monteagudo I (2019) Estado actual del tratamiento con infiltraciones intraarticulares en la artritis idiopática juvenil. Reumatol Clínica 15(2):69–72CrossRef
4.
Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML et al (2019) 2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Care Res 71(6):717–734CrossRef
5.
van Rossum MAJ, Fiselier TJW, Franssen MJAM, Zwinderman AH, ten Cate R, van Suijlekom-Smit LWA et al (1998) Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Arthritis Rheum 41(5):808–816CrossRef
6.
Burgos-Vargas R (2002) A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis 61(10):941–942CrossRef
7.
Bertamino M, Rossi F, Pistorio A, Lucigrai G, Valle M, Viola S et al (2010) Development and initial validation of a radiographic scoring system for the hip in juvenile idiopathic arthritis. J Rheumatol 37(2):432–439CrossRef
8.
Shelmerdine SC, Di Paolo PL, Tanturri de Horatio L, Malattia C, Magni-Manzoni S, Rosendahl K (2018) Imaging of the hip in juvenile idiopathic arthritis. Pediatr Radiol. 48(6):811–7CrossRef
Metadata
Title
In response to comment on “Hip involvement in children with enthesitis-related arthritis (ERA) is associated with poor outcomes in adulthood” by Ferjani H L et al. 
Authors
R. Naveen
Namita Mohindra
Neeraj Jain
Sanjukta Majumder
Amita Aggarwal
Publication date
01-03-2022
Publisher
Springer International Publishing
Published in
Clinical Rheumatology / Issue 3/2022
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-021-06021-x

Other articles of this Issue 3/2022

Clinical Rheumatology 3/2022 Go to the issue

ACKNOWLEDGMENTS

Acknowledgement to Referees 2021

Original Article

Diagnostic difficulty, delayed diagnosis, and increased tendencies of surgical treatment in fibromyalgia syndrome

Original Article

A retrospective analysis of antineutrophil cytoplasmic antibody-associated vasculitis aiming for an equation prediction end-stage renal disease

Original Article

Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 study

Brief Report

The untapped potential of Instagram to facilitate rheumatology academia

Original Article

Insulin resistance in children with juvenile systemic lupus erythematosus and ınvestigation of the possibly responsible factors
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits